Predict your next investment

Corporation
HEALTHCARE | Biotechnology
vcel.com

See what CB Insights has to offer

Stage

IPO | IPO

Total Raised

$17.6M

Date of IPO

2/4/1997

Market Cap

2.62B

Stock Price

53.24

About Vericel

Vericel, formerly Aastrom Biosciences, develops, manufactures, and markets expanded autologous cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Vericel is also marketing Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.

Vericel Headquarter Location

64 Sidney Street

Cambridge, Massachusetts, 02139,

United States

617-588-5555

Latest Vericel News

Vericel Corporation Investors: Company Investigated by the Portnoy Law Firm

Jul 22, 2021

07/22/2021 | 08:02am EDT Message : *Required fields LOS ANGELES, July 22, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Vericel Corporation ("Vericel" or the "Company") (NASDAQ: VCEL) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 310-692-8883 or email : lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com . The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. Vericel announced on May 7, 2019 that the company would enter into an exclusive license agreement in North America with MediWound Ltd. to commercialize NexoBrid, a product under development by MediWound for debridement of severe thermal burns. Then, on June 29, 2021, MediWound issued a press release "announc[ing] it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) seeking approval of NexoBrid® for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns." It was disclosed by MediWound that following completion of its review of the BLA, the FDA "determined that the application cannot be approved in its present form. The FDA identified issues related to the Chemistry, Manufacturing and Controls ('CMC') section of the BLA and requested additional CMC information." It was further disclosed by MediWound that "[t]he FDA also stated that an inspection of NexoBrid's manufacturing facilities in Israel and Taiwan, are required before the FDA can approve the BLA, but it was unable to conduct the required inspections during the current review cycle due to COVID-related travel restrictions. The FDA stated that it will continue to monitor the public health situation as well as travel restrictions and is actively working to define an approach for scheduling outstanding inspections. In addition, the CRL cited certain observations identified during good clinical practice (GCP) inspections related to the U.S. Phase 3 study (DETECT), and requested the company to provide its perspective on the potential impact, if any, of these observations on the efficacy findings in the study" On June 29, 2021, Vericel's stock price fell $10.04, or 14.81%, on this news, to close at $57.77. Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Vericel

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Vericel is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,708 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Vericel Patents

Vericel has filed 5 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Cell biology
  • Continuous distributions
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/25/2013

7/3/2018

Tires, Fluid dynamics, Bones of the pelvis, Continuous distributions, Hydrology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/25/2013

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/3/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Tires, Fluid dynamics, Bones of the pelvis, Continuous distributions, Hydrology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Vericel Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Vericel Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.